Patient and transplantation characteristics
| Factor . | n (%) . |
|---|---|
| Total no. of patients | 864 |
| Year of transplantation | |
| 1990-1995 | 289 (33) |
| 1996-2000 | 278 (32) |
| 2001-2005 | 238 (28) |
| 2006-2007 | 59 (7) |
| Age | |
| Younger than 10 y | 193 (22) |
| 10-17 y | 108 (13) |
| 18-35 y | 191 (22) |
| 36 y or older | 372 (43) |
| Median (range) | 32 (0.2-69) |
| Sex | |
| Male | 530 (61) |
| Female | 334 (39) |
| CMV serostatus | |
| Recipient negative, donor negative | 340 (39) |
| Recipient negative, donor positive | 107 (12) |
| Recipient positive | 417 (48) |
| Disease | |
| ALL | 141 (16) |
| AML | 193 (22) |
| CML | 179 (21) |
| MDS/MPD | 72 (8) |
| NHL | 63 (7) |
| Other malignancies | 52 (7) |
| SAA/FA | 55 (6) |
| Immune deficiency | 25 (3) |
| Storage disorder | 82 (9) |
| Disease risk* | |
| Standard | 431 (50) |
| High | 433 (50) |
| Donor type | |
| Matched sibling | 315 (36) |
| Mismatched sibling | 24 (3) |
| Well-matched URD | 79 (9) |
| Partially matched URD | 108 (13) |
| Mismatched URD | 126 (15) |
| Single UCB | 89 (10) |
| Double UCB | 123 (14) |
| Conditioning | |
| Myeloablative | 736 (85) |
| Nonmyeloablative | 128 (15) |
| GVHD prophylaxis | |
| CSA/MTX | 411 (48) |
| CSA/MMF | 195 (23) |
| CSA/MP | 98 (11) |
| T-cell depletion | 112 (13) |
| MTX/ATG/prednisone | 33 (4) |
| Tacrolimus/MTX | 5 (< 1) |
| Tacrolimus | 10 (1) |
| Factor . | n (%) . |
|---|---|
| Total no. of patients | 864 |
| Year of transplantation | |
| 1990-1995 | 289 (33) |
| 1996-2000 | 278 (32) |
| 2001-2005 | 238 (28) |
| 2006-2007 | 59 (7) |
| Age | |
| Younger than 10 y | 193 (22) |
| 10-17 y | 108 (13) |
| 18-35 y | 191 (22) |
| 36 y or older | 372 (43) |
| Median (range) | 32 (0.2-69) |
| Sex | |
| Male | 530 (61) |
| Female | 334 (39) |
| CMV serostatus | |
| Recipient negative, donor negative | 340 (39) |
| Recipient negative, donor positive | 107 (12) |
| Recipient positive | 417 (48) |
| Disease | |
| ALL | 141 (16) |
| AML | 193 (22) |
| CML | 179 (21) |
| MDS/MPD | 72 (8) |
| NHL | 63 (7) |
| Other malignancies | 52 (7) |
| SAA/FA | 55 (6) |
| Immune deficiency | 25 (3) |
| Storage disorder | 82 (9) |
| Disease risk* | |
| Standard | 431 (50) |
| High | 433 (50) |
| Donor type | |
| Matched sibling | 315 (36) |
| Mismatched sibling | 24 (3) |
| Well-matched URD | 79 (9) |
| Partially matched URD | 108 (13) |
| Mismatched URD | 126 (15) |
| Single UCB | 89 (10) |
| Double UCB | 123 (14) |
| Conditioning | |
| Myeloablative | 736 (85) |
| Nonmyeloablative | 128 (15) |
| GVHD prophylaxis | |
| CSA/MTX | 411 (48) |
| CSA/MMF | 195 (23) |
| CSA/MP | 98 (11) |
| T-cell depletion | 112 (13) |
| MTX/ATG/prednisone | 33 (4) |
| Tacrolimus/MTX | 5 (< 1) |
| Tacrolimus | 10 (1) |
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; MPD, myeloproliferative disease; NHL, non-Hodgkin lymphoma; SAA, severe aplastic anemia; FA, Fanconi anemia; CSA, cyclosporine A; MTX, methotrexate; MMF, mycophenolate mofetil; MP, methylprednisolone; and ATG, antithymocyte globulin.
Standard risk indicates acute leukemia in CR1 or CR2, CML in first chronic phase, MDS without excess blasts, or nonmalignant diseases. High risk indicates all others.